Home >> Signaling Pathways >> DNA Damage/DNA Repair

DNA Damage/DNA Repair

Products for  DNA Damage/DNA Repair

  1. Cat.No. Product Name Information
  2. GC32741 CCT-251921 CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM. CCT-251921  Chemical Structure
  3. GC18053 CCT241533 A selective Chk2 inhibitor CCT241533  Chemical Structure
  4. GC17105 CCT241533 hydrochloride A selective Chk2 inhibitor CCT241533 hydrochloride  Chemical Structure
  5. GC14772 CCT244747 Potent and selective CHK1 inhibitor CCT244747  Chemical Structure
  6. GC19093 CCT245737 CCT245737 is a orally active and seletive Chk1 inhibitor, with an IC50 of 1.3 nM. CCT245737  Chemical Structure
  7. GC35628 Cdc7-IN-1 Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death. Cdc7-IN-1  Chemical Structure
  8. GC62427 Cdc7-IN-5 Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle. Cdc7-IN-5  Chemical Structure
  9. GC12425 CDK inhibitor II CDK inhibitor II  Chemical Structure
  10. GC38899 CDK ligand for PROTAC hydrochloride CDK ligand for PROTAC hydrochloride  Chemical Structure
  11. GC62168 CDK-IN-6 CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a CDK inhibitor with anticancer activities. CDK-IN-6  Chemical Structure
  12. GC63499 CDK12-IN-2 CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12. CDK12-IN-2  Chemical Structure
  13. GC35632 CDK2-IN-4 CDK2-IN-4 is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM). CDK2-IN-4  Chemical Structure
  14. GC65190 CDK4/6-IN-11 CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader. CDK4/6-IN-11  Chemical Structure
  15. GC35633 CDK4/6-IN-2 CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively. CDK4/6-IN-2  Chemical Structure
  16. GC35634 CDK4/6-IN-3 CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor with Kis of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a Ki of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma. CDK4/6-IN-3  Chemical Structure
  17. GC64802 CDK4/6-IN-6 CDK4/6-IN-6 (example A94) is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. CDK4/6-IN-6  Chemical Structure
  18. GC60680 CDK5 inhibitor 20-223 CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent. CDK5 inhibitor 20-223  Chemical Structure
  19. GC66009 CDK5-IN-3 CDK5-IN-3 (compound 11) is a potent and selective CDK5 inhibitor, with IC50s of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD). CDK5-IN-3  Chemical Structure
  20. GC63980 CDK7-IN-2 CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1). CDK7-IN-2  Chemical Structure
  21. GC62596 CDK7-IN-3 CDK7-IN-3 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. CDK7-IN-3 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). CDK7-IN-3 induces apoptosis in tumor cells and has antitumor activity. CDK7-IN-3  Chemical Structure
  22. GC65434 CDK7/12-IN-1 CDK7/12-IN-1 is a selective CDK7/12 inhibitor with IC50s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth. CDK7/12-IN-1  Chemical Structure
  23. GC60681 CDK7/9 tide CDK7/9 tide is peptide substrate for CDK7 or CDK9. CDK7/9 tide  Chemical Structure
  24. GC33180 CDK8-IN-1 CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM. CDK8-IN-1  Chemical Structure
  25. GC30466 CDK8-IN-3 CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7. CDK8-IN-3  Chemical Structure
  26. GC33366 CDK8-IN-4 CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM. CDK8-IN-4  Chemical Structure
  27. GC35635 CDK9 Antagonist-1 CDK9 Antagonist-1  Chemical Structure
  28. GC12871 CDK9 inhibitor CDK9 inhibitor  Chemical Structure
  29. GC17359 CDK9 inhibitor 2 CDK9 inhibitor 2  Chemical Structure
  30. GC66475 CDK9-IN-10 CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811). CDK9-IN-10  Chemical Structure
  31. GC65262 CDK9-IN-13 CDK9-IN-13 (compound 38) is potent and selective CDK9 inhibitor, with an IC50 of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents. CDK9-IN-13  Chemical Structure
  32. GC64446 CDK9-IN-15 CDK9-IN-15 (compound 50) is a potent CDK9 inhibitor. CDK9-IN-15  Chemical Structure
  33. GC35636 CDK9-IN-7 CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC. CDK9-IN-7  Chemical Structure
  34. GC65247 CDK9-IN-8 CDK9-IN-8 is a highly effective and selective CDK9 inhibitor with an IC50 of 12 nM. CDK9-IN-8  Chemical Structure
  35. GC19096 CDKI-73 CDKI-73 is a potent CDK9 inhibitor with Ki of 4 nM; shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM). CDKI-73  Chemical Structure
  36. GC49307 cDPCP A DNA-crosslinking agent cDPCP  Chemical Structure
  37. GC32181 Cefradine (Cephradine) Cefradine (Cephradine) (Cefradine) is a broad-spectrum and orally active cephalosporin. Cefradine (Cephradine)  Chemical Structure
  38. GC19098 CeMMEC1 CeMMEC1 is an inhibitor of BRD4, and also has high affinity for TAF1, with an IC50 of 0.9 uM for TAF1, and a Kd of 1.8 uM for TAF1 (2). CeMMEC1  Chemical Structure
  39. GC19099 CeMMEC13 CeMMEC13 is a potent inhibitor of TAF1 (2) bromodomain, with an IC50 of 2.1 uM. CeMMEC13  Chemical Structure
  40. GC64261 Censavudine Censavudine (OBP-601; BMS-986001), a nucleoside analog, is a nucleoside reverse transcriptase inhibitor. Censavudine  Chemical Structure
  41. GC39484 Ceramides Mixture A mixture of ceramides Ceramides Mixture  Chemical Structure
  42. GC35668 CG-200745 CG-200745 (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. CG-200745 inhibits deacetylation of histone H3 and tubulin. CG-200745 induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. CG-200745 enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine and 5-Fluorouracil (5-FU; ). CG-200745 induces apoptosis and has anti-tumour effects. CG-200745  Chemical Structure
  43. GC14526 CGK733 ATM/ATR inhibitor,potent and selective CGK733  Chemical Structure
  44. GC60692 CH-0793076 TFA CH-0793076 (TP3076) TFA, a hexacyclic camptothecin analog, is active drug and major metabolite of TP300. CH-0793076 TFA inhibits DNA topoisomerase I with an IC50 of 2.3 μM. CH-0793076 TFA is efficacious against cells expressing BCRP (breast cancer resistance protein). CH-0793076 TFA  Chemical Structure
  45. GC18536 Chartreusin Chartreusin is an antibiotic originally isolated from S. Chartreusin  Chemical Structure
  46. GC64942 CHDI-390576 CHDI-390576, a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor with IC50s of 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9, respectively, shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform. CHDI-390576  Chemical Structure
  47. GC32250 Chebulinic acid An ellagitannin with diverse biological activities Chebulinic acid  Chemical Structure
  48. GC16042 Chidamide Chidamide (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor. Chidamide  Chemical Structure
  49. GC15739 CHIR-124 Chk1 inhibitor,novel and potent CHIR-124  Chemical Structure
  50. GC33392 CHK-IN-1 CHK-IN-1 is an inhibitor of CHK1 and CHK2, with anti-proliferative activities. CHK-IN-1  Chemical Structure
  51. GC30106 CHK1 inhibitor CHK1 inhibitor (GDC-0575 analog) is an inhibitor of CHK1. CHK1 inhibitor  Chemical Structure
  52. GC33289 CHK1-IN-2 CHK1-IN-2 is a checkpoint kinase 1 (CHK1) inhibitor, with an IC50 of 6 nM. CHK1-IN-2  Chemical Structure
  53. GC35679 CHK1-IN-3 CHK1-IN-3 is a Checkpoint Kinase 1 (CHK1) inhibitor with an IC50 of 0.4 nM. CHK1-IN-3  Chemical Structure
  54. GC60698 Chk1-IN-5 Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model. Chk1-IN-5  Chemical Structure
  55. GC12908 Chlorambucil

    nitrogen mustard alkylating agent

    Chlorambucil  Chemical Structure
  56. GC60107 Chloroquinoxaline sulfonamide Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide  Chemical Structure
  57. GC35693 CI 972 (anhydrous) CI 972 (anhydrous) is a potent, orally active, and competitive inhibitor of purine nucleoside phosphorylase (PNP) (Ki=0.83 μM) under development as a T cell-selective immunosuppressive agent. CI 972 (anhydrous)  Chemical Structure
  58. GC65878 Cimpuciclib tosylate Cimpuciclib tosylate is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity. Cimpuciclib tosylate  Chemical Structure
  59. GC63476 Cirtuvivint Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research. Cirtuvivint  Chemical Structure
  60. GC18640 cis-9,10-Methyleneoctadecanoic Acid methyl ester cis-9,10-Methyleneoctadecanoic acid methyl ester is a cyclopropane fatty acid methyl ester. cis-9,10-Methyleneoctadecanoic Acid methyl ester  Chemical Structure
  61. GC11908 Cisplatin

    Cisplatin is one of the best and first metal-based chemotherapeutic drugs, which is used for wide range of solid cancers such as testicular, ovarian, bladder, lung, cervical, head and neck cancer, gastric cancer and some other cancers.

    Cisplatin  Chemical Structure
  62. GC52351 Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide A biotinylated and citrullinated α-enolase peptide Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide  Chemical Structure
  63. GC34536 CK1-IN-1 CK1-IN-1 is a casein kinase 1 (CK1) inhibitor extracted from patent WO2015119579A1, compound 1c, has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively. CK1-IN-1  Chemical Structure
  64. GC62337 CK2 inhibitor 2 CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC50 of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity. CK2 inhibitor 2  Chemical Structure
  65. GC39485 CK2/ERK8-IN-1 A dual inhibitor of CK2 and ERK8 CK2/ERK8-IN-1  Chemical Structure
  66. GC63800 CK7 CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367. CK7  Chemical Structure
  67. GC50105 CKD 602 Topoisomerase I inhibitor CKD 602  Chemical Structure
  68. GC38755 CKI-7 CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases. CKI-7  Chemical Structure
  69. GC47098 CL2-SN-38 (dichloroacetic acid salt) An antibody-drug conjugate containing SN-38 CL2-SN-38 (dichloroacetic acid salt)  Chemical Structure
  70. GC60714 CL2A-SN-38 An antibody-drug conjugate containing SN-38 CL2A-SN-38  Chemical Structure
  71. GC10509 Cladribine Apoptosis inducer in CLL cells Cladribine  Chemical Structure
  72. GC49852 Clindamycin (hydrochloride hydrate) Clindamycin (hydrochloride hydrate) is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin (hydrochloride hydrate)  Chemical Structure
  73. GC52171 Clindamycin-d3 (hydrochloride) Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin-d3 (hydrochloride)  Chemical Structure
  74. GC30245 CLK1-IN-1 CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (CLK1) inhibitor, with an IC50 of 2 nM. CLK1-IN-1  Chemical Structure
  75. GC15219 Clofarabine Antimetabolite,inhibit DNA polymerase and ribonucleotide reductase Clofarabine  Chemical Structure
  76. GC33320 CM-579 CM-579 is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells. CM-579  Chemical Structure
  77. GC35714 CM-579 trihydrochloride CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells. CM-579 trihydrochloride  Chemical Structure
  78. GC65426 CM-675 CM-675 is a dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitor, with IC50 values of 114 nM and 673 nM for PDE5 and HDAC1, respectively. CM-675  Chemical Structure
  79. GC62698 CMLD012612 CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity. CMLD012612  Chemical Structure
  80. GC33327 CMPD 7 CMPD 7 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay. CMPD 7  Chemical Structure
  81. GC33177 CNDAC CNDAC is a major metabolite of oral drug sapacitabine, and a nucleoside analog. CNDAC  Chemical Structure
  82. GC38382 CNDAC hydrochloride CNDAC hydrochloride is a metabolite of the orally active agent sapacitabine, and a nucleoside analog. CNDAC hydrochloride  Chemical Structure
  83. GC19110 COH29 COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity. COH29  Chemical Structure
  84. GC10812 Compound 401 DNA-PK and mTOR inhibitor Compound 401  Chemical Structure
  85. GC61965 Coralyne chloride Coralyne chloride is a protoberberine alkaloid with potent anti-cancer activities. Coralyne chloride acts as a potent topoisomerase I poison and induces Top I mediated DNA cleavage. Coralyne chloride can be used for preparing?coralyne derivatives?as DNA binding fluorescent probes. Coralyne chloride  Chemical Structure
  86. GC34165 Corin Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1. Corin  Chemical Structure
  87. GC16116 Costunolide A natural sesquiterpene lactone Costunolide  Chemical Structure
  88. GC35739 CP-10 CP-10 is a PROTAC connected by ligands for Cereblon and CDK, with highly selective, specific, and remarkable CDK6 degradation (DC50=2.1 nM). It inhibits proliferation of several haematopoietic cancer cells with impressive potency including multiple myeloma, and can still degrades mutated and overexpressed CDK6. CP-10  Chemical Structure
  89. GC16489 CP-466722 ATM inhibitor,potent and reversible CP-466722  Chemical Structure
  90. GC68455 CP681301 CP681301  Chemical Structure
  91. GC32565 CRA-026440 CRA-026440 is a potent, broad-spectrum HDAC inhibitor. CRA-026440  Chemical Structure
  92. GC67674 CRA-026440 hydrochloride CRA-026440 hydrochloride  Chemical Structure
  93. GC38412 Crotonoside A guanosine analog with diverse biological activities Crotonoside  Chemical Structure
  94. GC50404 CRT 0105950 Potent LIMK1/2 inhibitor CRT 0105950  Chemical Structure
  95. GC17231 CRT0044876 APE1 inhibitor, potent and selective CRT0044876  Chemical Structure
  96. GC65023 CTX-712 CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286). CTX-712  Chemical Structure
  97. GN10526 Cucurbitacin E Cucurbitacin E  Chemical Structure
  98. GC18028 CVT-313 A Cdk2 inhibitor CVT-313  Chemical Structure
  99. GC13037 CX-4945 (Silmitasertib) CX-4945 (Silmitasertib) (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'. CX-4945 (Silmitasertib)  Chemical Structure
  100. GC11325 CX-4945 sodium salt CX-4945 sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'. CX-4945 sodium salt  Chemical Structure
  101. GC14404 CX-5461 Pol I-mediated rRNA synthesis inhibitor CX-5461  Chemical Structure

Items 401 to 500 of 1356 total

per page
  1. 3
  2. 4
  3. 5
  4. 6
  5. 7

Set Descending Direction